FDA Issues Complete Response Letter for Lead Drug GTx-104, Citing Manufacturing & Non-Clinical Issues
GRCE sits 23% above its 52-week low of $1.79 on elevated volume (7.8× avg).
Summary
Grace Therapeutics received a Complete Response Letter from the FDA for its lead drug candidate GTx-104, citing issues related to manufacturing and non-clinical information, delaying potential approval.
Key Events · Product Development and Regulatory · GRCE
-
FDA Issues Complete Response Letter (CRL)
The U.S. Food and Drug Administration (FDA) issued a CRL for Grace Therapeutics' New Drug Application (NDA) for GTx-104, a drug for aneurysmal subarachnoid hemorrhage (aSAH).
-
Citations for CMC and Non-Clinical Issues
The CRL cited outstanding items related to Chemistry, Manufacturing, and Controls (CMC) and non-clinical information, including leachables data for product packaging, toxicology risk assessments, and manufacturing deficiencies.
-
No Additional Clinical Data Requested
The FDA did not request additional clinical data, indicating the clinical efficacy and safety profile of GTx-104 was not the reason for the CRL.
-
Company Plans Resubmission
Grace Therapeutics intends to request a Type A meeting with the FDA to clarify the path forward and plans to resubmit the NDA after addressing the identified issues.
Analysis · GRCE · Life Sciences
This 8-K confirms the significant setback for Grace Therapeutics as its lead drug candidate, GTx-104, received a Complete Response Letter from the FDA. While the news was previously reported, this filing provides the official details, clarifying that the issues are related to manufacturing and non-clinical aspects, rather than the clinical trial data itself. This distinction is crucial, as it suggests the core efficacy and safety profile of GTx-104 remains sound, potentially simplifying the path to resubmission compared to needing new clinical trials. However, the CRL still introduces an indefinite delay in potential market approval and commercialization, which is a material negative for a small-cap biopharma company reliant on its lead asset. The company's plan to engage with the FDA and resubmit indicates a continued commitment to GTx-104, but investors should anticipate increased costs and a prolonged timeline to market.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.5% of the 1531 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GRCE was trading at $2.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $66.7M. The 52-week trading range was $1.79 to $5.18. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.